#NewAseBioMember | "We believe that AseBio can serve as an important tool for expanding collaborations"
Meet our new member MedBioinformatics. We sponke with Ferran Sanz, Founding Partner, Member of the Board of Directors, and Scientific Advisor
AseBio. What does your company's work bring to the table and what is its strength?
Ferran Sanz. MedBioinformatics is a company dedicated to knowledge engineering in the biomedical and pharmaceutical fields. Our main strength is the worldwide reputation of our product, DISGENET.
AseBio. What is AseBio for you?
Ferran Sanz. We consider AseBio an excellent platform for collaboration and visibility in the biotech sector.
AseBio. When did you first hear about AseBio?
Ferran Sanz. I first heard about AseBio quite a few years ago, and I have always perceived it as a key player among business organizations.
AseBio. What do you expect from being part of an association like AseBio?
Ferran Sanz. We believe that AseBio can serve as an important tool for expanding collaborations, enhancing visibility, and increasing the influence of MedBioinformatics.
AseBio. What is the biggest challenge facing the biotech sector or your company?
Ferran Sanz. The biggest challenge for MedBioinformatics is to continue expanding the global impact of our biomedical and pharmaceutical knowledge engineering services—something we have already accomplished with DISGENET.y.